Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly & Co. Director Gabrielle Sulzberger acquired additional common stock through a compensation deferral plan, increasing her beneficial ownership.

Summary

• Gabrielle Sulzberger, a Director at Eli Lilly & Co. (LLY), acquired common stock on November 17, 2025.
• She acquired 4.853 shares of common stock at a price of $1,021.7 per share.
• These 4.853 shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service.
• She also acquired an additional 215.327 shares of common stock on the same date at a price of $1,021.7 per share.
• Following these transactions, her direct beneficial ownership in Eli Lilly & Co. common stock increased to 2,948.32 shares.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased beneficial ownership in the company, partly through a compensation deferral plan, which generally aligns management interests with shareholders. This is a routine, slightly positive signal of confidence.

Positives

• A Director, Gabrielle Sulzberger, increased her beneficial ownership in Eli Lilly & Co. common stock, aligning her interests further with shareholders.
• The acquisition of 4.853 shares resulted from deferring cash compensation into stock units, demonstrating a commitment to long-term company performance.

Future Outlook

The 4.853 shares acquired through the Lilly Directors' Deferral Plan will be settled in shares of common stock following the reporting person's separation from service.

Management Comments

• The shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Insider transaction reports, such as Form 4 filings, are routine disclosures for publicly traded companies. Director compensation deferral plans into company stock are a common practice to align the interests of board members with long-term shareholder value, particularly in large pharmaceutical companies like Eli Lilly & Co.

Comparison to Industry Standards

• Director stock ownership and compensation deferral plans are standard corporate governance practices within the pharmaceutical industry and across large-cap companies. This transaction aligns with typical industry approaches to executive and director compensation, aiming to foster long-term commitment and performance alignment.

Corporate Governance

Related Party Transactions

• Acquisition of common stock by Director Gabrielle Sulzberger from Eli Lilly & Co. through a compensation deferral plan, representing a transaction between a company insider and the issuer.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director, particularly through a compensation deferral, suggests stronger alignment of management's long-term interests with shareholder value.
• Director: Gabrielle Sulzberger's personal stake in the company's performance is increased, potentially influencing her decision-making to favor long-term growth.

Next Steps

• Settlement of deferred stock units into common stock following the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director acquired shares, partly through a compensation deferral plan. While it shows alignment of interests, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard disclosure of insider ownership changes.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Beneficial Ownership